Author

Sunil Sharma

Clemson UniversityPrimary ORCID profile (0000-0001-5892-2671 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Sunil SharmaiD3 papers · Clemson University

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Organism:zebrafish· 1

Frequent Co-Authors

Alexis Weston· 1 shared Arnob SarkeriD· 1 shared Erin KelleyiD· 1 shared Erkut Hasan BorazanciiD· 1 shared Frank Yung-Chin TsaiiD· 1 shared John A. AltiniD· 1 shared Jorge Soria‐BustosiD· 1 shared Justin Moser· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Alexis Weston

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Aryl Hydrocarbon Receptor (Ahr) Pathway Drives TBBPA Induced Cartilage Development Defects.

Kanchaka Senarath Pathirajage, Sunil Sharma, Tyler Johnson, Arnob Sarker, Subham Dasgupta

This study identifies the Ahr-Cyp1a axis and reactive oxygen species (ROS) as key mediators of TBBPA-induced craniofacial cartilage defects in zebrafish.

bioRxiv · Sep 11, 2026 · PreprintPharmacology & Toxicology

Preclinical Proof of Concept for a personalized SNAPTM-TIL (Specific Neo-Antigen Peptides -TIL) therapy platform

Tithi Ghosh, Erin Kelley, Jorge Soria‐Bustos, Trason G. Thode, Serina Ng, Taylor Bargenquast, Alexis Weston, Ryan Rodriguez del Villar, Mohan Rao Kaadige, Erkut Hasan Borazanci, Michael S. Gordon, Justin Moser, Frank Yung-Chin Tsai, Saul J. Priceman, Stephen J. Forman, , Sunil Sharma

This paper demonstrates a personalized SNAP-TIL therapy platform that improves TIL efficacy by enriching them with neoantigen-reactive T-cells, achieving high CD3+ cell content and significant tumor growth inhibition in preclinical models.

OncoImmunology · Jul 5, 2026Peer-reviewedImmunology